DARWIN GLOBAL MANAGEMENT LTD
Q1 2025 Form 13-F

ST. HELIER
CIK 0001839209 · CRD 312512 · Exempt reporting adviser
$1.5B Reported Value Total

DARWIN GLOBAL MANAGEMENT, LTD. reports under management (AUM).

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-30
Reported value
$1.5B
Quarter over quarter
+11.6%
Holdings
3
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Sarah Monime
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2025 13F record

Q1 2025 13F filing summary

Q1 2025 Form 13F portfolio summary
Period of report March 31, 2025
Filed May 15, 2025
Form 13F-HR
Reported value $1.5B
Positions 3
Change in reported value +38.6%
New positions 1
Exited positions 4
Position turnover 71.4%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
5 $4.0B
Q2 2026 13F
Filed Aug 14, 2026
5 $3.8B
Q1 2026 13F
Filed May 15, 2026
6 $3.8B
Q4 2025 13F
Filed Feb 17, 2026
6 $4.9B
Q3 2025 13F
Filed Nov 14, 2025
5 $3.6B
Q2 2025 13F
Filed Aug 14, 2025
5 $2.4B
Q1 2025 13F
Filed May 15, 2025
3 $1.5B
Q4 2024 13F
Filed Feb 14, 2025
6 $1.1B
Q3 2024 13F
Filed Nov 14, 2024
5 $1.2B
Q2 2024 13F
Filed Aug 14, 2024
9 $859.5M
Q1 2024 13F
Filed May 15, 2024
12 $751.2M
Q4 2023 13F
Filed Feb 14, 2024
8 $509.5M
Q3 2023 13F
Filed Nov 14, 2023
3 $284.2M
Q2 2023 13F
Filed Aug 14, 2023
3 $611.7M
Q1 2023 13F
Filed May 15, 2023
4 $365.6M
Q4 2022 13F
Filed Feb 14, 2023
4 $160.6M
Q3 2022 13F
Filed Nov 14, 2022
2 $66.4M
Q2 2022 13F
Filed Aug 15, 2022
1 $188.2M
Q1 2022 13F
Filed May 16, 2022
1 $110.2M
Q4 2021 13F
Filed Feb 14, 2022
13 $654.6M

4 earlier quarters on file — choose one from the quarter menu above.

Top 3 holdings · Q1 2025

Largest Q1 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 INSM INSMED INC $1.2B 82.08%
2 VRNA VERONA PHARMA PLC $246.0M 16.81%
3 ALLO ALLOGENE THERAPEUTICS INC $16.2M 1.11%

Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings